Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. Prosperi MC, et al. Among authors: di biagio a, di pietro m, di giambenedetto s. BMC Med Inform Decis Mak. 2011 Jun 14;11:40. doi: 10.1186/1472-6947-11-40. BMC Med Inform Decis Mak. 2011. PMID: 21672248 Free PMC article.
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
Kabra M, Barber TJ, Allavena C, Marcelin AG, Di Giambenedetto S, Pasquau J, Gianotti N, Llibre JM, Rial-Crestelo D, De Miguel-Buckley R, Blick G, Turner M, Harrison C, Wynne T, Verdier G, Parry CM, Jones B, Okoli C, Donovan C, Priest J, Letang E. Kabra M, et al. Among authors: di giambenedetto s. Open Forum Infect Dis. 2023 Oct 27;10(11):ofad526. doi: 10.1093/ofid/ofad526. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38033982 Free PMC article.
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.
Kumar P, Clarke AE, Jonsson-Oldenbüttel C, Deltoro MG, Di Giambenedetto S, Brites C, Hocqueloux L, Lu PL, Oyee J, Oglesby A, Wynne B, Jones B, Evitt LA, Fox D, Kisare M, Priest J. Kumar P, et al. Among authors: di giambenedetto s. AIDS Behav. 2024 Sep 3. doi: 10.1007/s10461-024-04479-9. Online ahead of print. AIDS Behav. 2024. PMID: 39225890
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.
Katlama C, Bisshop F, Bogner J, Pérez Elías MJ, Di Giambenedetto S, Clarke E, Hodder S, Nwokolo N, Ait-Khaled M, Oyee J, Grove R, Wynne B, Okoli C, Jones B, Kisare M. Katlama C, et al. Among authors: di giambenedetto s. HIV Med. 2024 Jul;25(7):873-884. doi: 10.1111/hiv.13643. Epub 2024 May 17. HIV Med. 2024. PMID: 38760011 Clinical Trial.
Investigating seroprevalence of IgG antibodies against Monkeypox Virus (MPXV) in a cohort of people living with HIV (PLWH) in Rome, during the 2022 outbreak: Moving beyond traditional at-risk populations.
Salvo PF, Sanfilippo A, Baldin G, Iannone V, Ciccullo A, Farinacci D, Benvenuto D, Borghetti A, Di Giambenedetto S, Lombardi F. Salvo PF, et al. Among authors: di giambenedetto s. Travel Med Infect Dis. 2024 Sep 4;62:102757. doi: 10.1016/j.tmaid.2024.102757. Online ahead of print. Travel Med Infect Dis. 2024. PMID: 39241937 Free article.
Autochthonous dengue outbreak in Rome, Italy, in 2023.
Salvo PF, Baldin G, Raffaelli F, Ciccullo A, Borghetti A, Tamburrini E, Ricci R, Di Donato M, Di Giambenedetto S, Torti C. Salvo PF, et al. Among authors: di giambenedetto s. J Travel Med. 2024 Aug 24:taae111. doi: 10.1093/jtm/taae111. Online ahead of print. J Travel Med. 2024. PMID: 39180338
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
293 results